Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOR107
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
MOR107 is a synthetic peptide and selective agonist of the angiotensin II receptor type 2 (AT2R), developed as a potential antifibrotic and antineoplastic agent. It is classified as a lanthipeptide and was originally developed by Lanthio Pharma using proprietary technology later acquired by MorphoSys (now part of Novartis). The drug was investigated primarily for diseases involving tissue fibrosis such as diabetic nephropathy and other fibrotic conditions. Its mechanism involves activation of the protective arm of the renin-angiotensin system via AT2R agonism. Clinical development reached Phase 1 trials in healthy volunteers but has since been discontinued for all indications[1][3][4][5].
- Other names
- MOR107MOR-107MOR 107LP 2LP2LP-2LP2-3LP-2-3LP 2-3
02
Targets
AGTR2 (AT2)
Beyond the preview
Go deeper on MOR107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOR107.